LFA Joins Glaxo & HGS to Announce Lupus Drug Test Results

The Lupus Foundation of America (LFA) put out a press release yesterday with positive news about the second of two large-scale phase III clinical trials of "Benlysta" (belimumab), to treat lupus.

This is big news because both trials of the drug developed by Human Genome Sciences (HGS)have "succeeded in meeting their primary endpoints", which is the safe way to say that it seems to work as planned. 

These results should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA) for treatment of lupus and pharmaceutical teammates Glaxo Smith-Kline (Glaxo) and HGS are expected to submit their marketing plans for the drug in early 2010. 

In the race to have the "first drug specifically for the treatment of lupus", Benlysta seems to be out in front. Benlysta acts to inhibit stimulation of B-cell development, and thus to restore the potential for autoantibody-producing B cells to undergo the normal cell life cycle that has been upset by lupus. 

Leave a comment



About

This time, it IS lupus

Archives


 

Recent Entries